Loading organizations...
§ Private Profile · Liège, Liege, Belgium
Provides cell therapy productivity solutions and GMP services for biotech and pharmaceutical applications, focused on cryopreservation.
Cell Matters is a biotechnology service provider that delivers cell therapy productivity solutions and Good Manufacturing Practice (GMP) services focused on cryopreservation for clients in unspecified locations. The organization assists biotechnology and pharmaceutical companies in optimizing cell processing and storage protocols to support the development of advanced therapies. Operating primarily within the broader cell and gene therapy sector, the entity utilizes a fee-for-service model to provide specialized manufacturing and consulting capabilities. Specific operational metrics, including total funding raised, current valuation figures, and exact employee counts, remain undisclosed at this time. Furthermore, the organization has not publicly disclosed its primary lead investors, strategic partners, or a list of recognizable enterprise customers utilizing its cryopreservation platforms. The exact founding year and the identities of the original founders of Cell Matters are currently unavailable in public records.
Cell Matters has raised $870K across 1 funding round.
Cell Matters has raised $870K in total across 1 funding round.
Cell Matters has raised $870K in total across 1 funding round.
Cell Matters's investors include Jean-Pierre Delwart, Gesval, Marc Foidart.
Cell Matters has raised $870K across 1 funding round. Most recently, it raised $870K Series A in January 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 23, 2018 | $870K Series A | — | Jean Pierre Delwart, Gesval, Marc Foidart | Announced |